Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Vemurafenib for leptomeningeal melanomatosis.

Literature DB >> 23460716

Vemurafenib for leptomeningeal melanomatosis.

Niklas Schäfer¹, Björn Scheffler, Moritz Stuplich, Christina Schaub, Sied Kebir, Claudia Rehkämper, Frederick Mack, Pitt Niehusmann, Matthias Simon, Susanne Greschus, Klaus Kuchelmeister, Ulrich Herrlinger, Martin Glas.

Abstract

Entities: Chemical Disease

Mesh：

Substances：

Year: 2013 PMID： 23460716 DOI： 10.1200/JCO.2012.46.5773

Source DB: PubMed Journal: J Clin Oncol ISSN： 0732-183X Impact factor: 44.544

Keyword Cloud
Cited

× No keyword cloud information.

12 in total

Review 1. Combination therapy with BRAF and MEK inhibitors for melanoma: latest evidence and place in therapy.

Authors: Zeynep Eroglu; Antoni Ribas
Journal: Ther Adv Med Oncol Date: 2016-01 Impact factor: 8.168

2. Two cases of primary leptomeningeal melanomatosis mimicking subacute meningitis.

Authors: Sabina Aslan; Rahsan Gocmen; Nazire Pınar Acar; Farid Khasiyev; Ekim Gumeler; Figen Soylemezoglu; Aslı Tuncer; Ethem Murat Arsava; Mehmet Akif Topçuoglu; Isin Unal Cevik
Journal: Neuroradiol J Date: 2017-06-19

3. Rapid progression of intracranial melanoma metastases controlled with combined BRAF/MEK inhibition after discontinuation of therapy: a clinical challenge.

Authors: Daniel N Cagney; Brian M Alexander; F Stephen Hodi; Elizabeth I Buchbinder; Patrick A Ott; Ayal A Aizer
Journal: J Neurooncol Date: 2016-07-11 Impact factor: 4.130

4. Predictors of survival in metastatic melanoma patients with leptomeningeal disease (LMD).

Authors: Sherise D Ferguson; Shivani Bindal; Roland L Bassett; Lauren E Haydu; Ian E McCutcheon; Amy B Heimberger; Jing Li; Barbara J O'Brien; Nandita Guha-Thakurta; Michael T Tetzlaff; Hussein Tawbi; Michael A Davies; Isabella C Glitza
Journal: J Neurooncol Date: 2019-03-07 Impact factor: 4.130

10. Prolonged survival of a patient with metastatic leptomeningeal melanoma treated with BRAF inhibition-based therapy: a case report.

Authors: Dae Won Kim; Edelyn Barcena; Urvi N Mehta; Michelle L Rohlfs; Ashok J Kumar; Marta Penas-Prado; Kevin B Kim
Journal: BMC Cancer Date: 2015-05-13 Impact factor: 4.430

Vemurafenib for leptomeningeal melanomatosis.

Review 1. Combination therapy with BRAF and MEK inhibitors for melanoma: latest evidence and place in therapy.

2. Two cases of primary leptomeningeal melanomatosis mimicking subacute meningitis.

3. Rapid progression of intracranial melanoma metastases controlled with combined BRAF/MEK inhibition after discontinuation of therapy: a clinical challenge.

4. Predictors of survival in metastatic melanoma patients with leptomeningeal disease (LMD).

5. Leptomeningeal metastasis from solid tumors: a single center experience in Chinese patients.

Review 6. Managing leptomeningeal melanoma metastases in the era of immune and targeted therapy.

Review 7. Leptomeningeal Metastases: New Opportunities in the Modern Era.

Review 8. Hairy cell leukemia-new genes, new targets.

Review 9. Advances in Diagnosis and Treatment for Leptomeningeal Disease in Melanoma.

10. Prolonged survival of a patient with metastatic leptomeningeal melanoma treated with BRAF inhibition-based therapy: a case report.